Business
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative
About this update from Ardelyx, Inc.
[{"type":"text","content":"FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan Rodriguez, an industry veteran with over 25 years of global pharmaceutical experience, as the company's first chief commercial officer. Ms. Rodriguez will be responsible for leading the commercial organization, including launch planning and strategy, as well as alliance management and business development. \n\n \n \n \n \n \n \n\n \n\"We are very fortunate to have someone of Susan's caliber and successful track record join our management team,\" said Mike Raab, president and chief executive officer of Ardelyx. \"Susan has a remarkable history of global marketing and sales leadership and has built commercial teams responsible for multi-billion-dollar drugs and portfolios. During her tenure at Abbott, she led the establishment of its U.S. renal commercial organization and oversaw numerous successful product launches. The implementation of her strategies resulted in favorable reimbursement and market access for patients. The breadth and depth of her relevant experience will serve us extremely well as we approach the potential approval of tenapanor in mid-2021. Ultimately, Susan's energy and strategic orientation, and her expertise and leadership will be instrumental to help advance us towards our goal of making tenapanor available to the many chronic kidney disease patients on dialysis whose serum phosphorus levels are uncontrolled.\" \nSusan Rodriguez added, \"I am thrilled to join Ardelyx at this exciting juncture as we approach the potential launch of tenapanor, the first non-binder treatment option for dialysis patients suffering from chronic kidney disease. The company is in a unique position with compelling clinical data for a drug candidate that is wholly-owned in major markets such as the U.S. and Europe. My passion is launching, establishing and building global brands and I look forward to leveraging the solid foundation the Ardelyx team has already built to position tenapanor for commercial success.\"\nMs. Rodriguez is a seasoned healthcare executive with extensive leadership experience across pharmaceutical, biopharma, hospital products, ...